跳至主要内容
临床试验/NCT02370342
NCT02370342撤回不适用

Robot-Assisted Laparoscopic HIFU (High-Intensity Focused Ultrasound) for Thermal Ablative Therapy of Small Renal Mass: Corroborating With Robot-Assisted Laparoscopic Partial Nephrectomy Specimens

University of Southern California4 个研究点 分布在 1 个国家开始时间: 2017年12月18日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
撤回
试验地点
4
主要终点
Necrosis volume

研究概览

简要总结

This clinical trial studies a type of ultrasound called robot-assisted laparoscopic high-intensity focused ultrasound for performing thermal ablative therapy, or sound wave therapy, in treating patients with small kidney masses undergoing partial removal of the kidney. The robot-assisted ultrasound probe takes images of the kidney to help doctors locate the mass. The probe then uses high frequency sound waves to target and ablate (or destroy) the kidney mass, which may be a cancerous tumor or benign tissue. Surgery is then performed to remove the part of the kidney with the mass. Robot-assisted laparoscopic high-intensity focused ultrasound for thermal ablative therapy may be safer and help doctors see the tumor better when performing kidney surgery.

详细描述

PRIMARY OBJECTIVES:

I. To evaluate the efficacy of laparoscopic high-intensity focused ultrasound (HIFU) for the treatment of localized primary renal cancer to evaluate histological accuracy in successful ablation of the small renal mass, matched with intraoperative targeting.

SECONDARY OBJECTIVES:

I. To evaluate the safety and toxicity of laparoscopic HIFU for patients with primary renal cancer.

II. To evaluate the technical success of laparoscopic HIFU ablation.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Presence of an enhancing solid renal mass =< 3.0 cm on radiological examination
  • Tumors with a depth of not greater than 3.0 cm from a laparoscopically accessible surface-meaning no part of the tumor should be deeper than 3.0 cm from the surface
  • Patients with solitary kidneys, bilateral renal tumors, compromised renal function (baseline creatinine > 1.4)
  • Subjects must have given written informed consent
  • Previous chemotherapy, and/or biological therapy for cancer are permitted provided that the acoustic properties of the tumor were not affected, but the subject should have recovered from the effects of these or of any prior surgery
  • Subjects must be free of any clinically significant disease other than cancer that would interfere with the study evaluations
  • Absolute neutrophil count (ANC) >= 1500 mm^-3
  • Platelet count >= 100,000 mm^-3
  • Hemoglobin >= 10 g/dl
  • Prothrombin time (PT) =< 1.5 times upper limit of laboratory normal (ULN)
  • Activated partial thromboplastin time =< 1.5 times ULN
  • Urea and serum creatinine < 2.5 times ULN
  • Total bilirubin < 1.5 times ULN
  • Aspartate aminotransferase (AST) =< 3 times ULN
  • Alkaline phosphatase < 2 times ULN, unless arising from bone

排除标准

  • < 90% solid component on screening cross-sectional imaging
  • Subjects deemed unsuitable candidates and not medically optimized for partial nephrectomy
  • Tumors greater than 3.0 cm at their widest point
  • Subjects with tumors lying < 1 cm from sensitive structures such as the ureter, renal vessels or adjacent bowel
  • Subjects on concurrent anticoagulant, or immunosuppressive medication
  • Subjects on anti-cancer medication whether biologic or pharmaceutical
  • Women who are pregnant or nursing (pregnancy test to be performed within 24 hours prior to HIFU treatment)
  • Subjects assessed by consultant anesthetist as unsuitable for general anesthetic
  • Subjects having had prior ablation therapy on the same tumor

研究组 & 干预措施

Treatment (robot-assisted laparoscopic HIFU)

Experimental

Patients undergo robot-assisted laparoscopic HIFU thermal ablative therapy during partial nephrectomy.

干预措施: Robot-Assisted Laparoscopic Surgery (Procedure)

Treatment (robot-assisted laparoscopic HIFU)

Experimental

Patients undergo robot-assisted laparoscopic HIFU thermal ablative therapy during partial nephrectomy.

干预措施: High-Intensity Focused Ultrasound Ablation (Procedure)

Treatment (robot-assisted laparoscopic HIFU)

Experimental

Patients undergo robot-assisted laparoscopic HIFU thermal ablative therapy during partial nephrectomy.

干预措施: Therapeutic Laparoscopic Surgery (Procedure)

Treatment (robot-assisted laparoscopic HIFU)

Experimental

Patients undergo robot-assisted laparoscopic HIFU thermal ablative therapy during partial nephrectomy.

干预措施: Sonatherm 600i Ultrasonic Lesion Generating System (Device)

结局指标

主要结局

Necrosis volume

时间窗: Baseline (day of surgery)

Ablation area of the kidney mass will be compared to the planned area under histopathologic review. Analyzed using a one-sided one sample T-test.

Planned ablation volume

时间窗: Baseline (day of surgery)

Ablation area of the kidney mass will be compared to the planned area under histopathologic review. Analyzed using a one-sided one sample T-test.

次要结局

  • Disease free interval(From the date of treatment to the date of local or distant failure or until date of death, assessed up to 4 years)
  • Overall success rate, measured as the combination of achieving local control of kidney cancer and demonstration of a favorable safety profile evidenced by enumeration of all adverse events by type, severity, and frequency(Up to 4 years)
  • Tumor response(Up to 4 years)
  • Time to local failure(From the date of treatment to the time to local failure, assessed up to 4 years)
  • Time to distant failure(From the date of treatment to the time to documented metastatic disease, assessed up to 4 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验